2 Under-the-Radar Pharma M&A Targets for 2018 Post author:Sam Post published:January 10, 2018 Post category:BioPharma A look at why these two biopharma companies could have targets on their backs. Source: BioSpace You Might Also Like This Bay Area Biotech Snags $293 Million Pain Drug Pact With Novartis AG May 7, 2017 AbbVie Presents New Positive Late-Breaking Data from Two Phase 3 Psoriasis Trials of Risankizumab… February 18, 2018 Tonix Pharma Prices Public Offering Of 1,800,000 Shares Of Common Stock March 29, 2017
AbbVie Presents New Positive Late-Breaking Data from Two Phase 3 Psoriasis Trials of Risankizumab… February 18, 2018
